Phase Ib PAVO Study: Subcutaneous Daratumumab in Relapsed/Refractory Multiple Myeloma

December 3-6, 2016; San Diego, California
This open-label, multicenter, dose-finding phase Ib trial suggests that subcutaneous daratumumab plus rHuPH20 is safe and effective in patients with relapsed/refractory MM.
Format: Microsoft PowerPoint (.ppt)
File Size: 619 KB
Released: December 7, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

In this slideset from Clinical Care Options, experts provide insights on emerging CAR T-cell strategies for myeloma.

Noopur Raje, MD Released: December 3, 2020

CCO Conference Coverage of ASH 2020 with downloadable slides and experts’ commentaries of clinically relevant studies

Hanny Al-Samkari, MD John M. Burke, MD Jorge Cortes, MD Amy E. DeZern, MD, MHS Shaji Kumar, MD Sagar Lonial, MD person default Mark A. Schroeder, MD Jeff P. Sharman, MD Sujit Sheth, MD Srdan Verstovsek, MD, PhD Eunice S. Wang, MD Released: December 2, 2020

From Clinical Care Options (CCO), expert commentary on key new developments in CAR T-cell therapy and a preview of CAR T-cell data at ASH 2020

Michael Wang, MD Released: December 1, 2020

CCO commentary from Shaji Kumar, MD, on key issues in the management of multiple myeloma

Shaji Kumar, MD Released: November 23, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue